株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

エピジェネティクス治療市場(〜2017年):急性骨髄性白血病、多発性骨髄腫および皮膚T細胞性リンパ腫におけるエピジェネティクス薬の高い市場潜在性

Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma

発行 GBI Research 商品コード 128635
出版日 ページ情報 英文 89 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
エピジェネティクス治療市場(〜2017年):急性骨髄性白血病、多発性骨髄腫および皮膚T細胞性リンパ腫におけるエピジェネティクス薬の高い市場潜在性 Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma
出版日: 2010年09月01日 ページ情報: 英文 89 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートは、エピジェネティクス治療市場について調査し、主要国別のエピジェネティクス薬市場規模および収益予測、各治療薬のパイプラインおよび市場潜在性分析、SWOT分析を含む主要企業のプロファイルなどを提供しており、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場の特徴:世界のエピジェネティクス市場

  • 疾病の概要
    • 骨髄異形成症候群
    • 皮膚T細胞性リンパ腫
  • エピジェネティクス薬
  • 米国
  • 欧州の主要5市場
  • 日本

第4章 詳細分析

  • イントロダクション
  • Vidaza (Azacitidine)
    • 適応
    • 作用機序
    • 収益予測
    • 要点
    • 市場潜在性
    • 要点
    • パイプライン分析
    • 要点
    • 治療薬プロファイル
  • Dacogen (Decitabine)
    • 適応
    • 作用機序
    • 収益予測
    • 要点
    • 市場潜在性
    • 要点
    • パイプライン分析
    • 要点
    • 治療薬プロファイル
  • Zolinza (Vorinostat)
    • 適応
    • 作用機序
    • 収益予測
    • 疾病の概要
    • 市場潜在性
    • 要点
    • パイプライン分析
    • 要点
    • 治療薬プロファイル
  • Istodax (Romidepsin)
    • 適応
    • 疾病の概要
    • 作用機序
    • 市場潜在性
    • 要点
    • パイプライン分析
    • 臨床研究:フェーズ別
    • 臨床研究:適応別
    • 要点
    • 治療薬プロファイル

第5章 競合情勢

  • Merck & Co.
    • 企業概要
    • 事業説明
    • SWOT分析
  • Celgene Corporation
    • 企業概要
    • 事業説明
    • SWOT分析
  • エーザイ
    • 企業概要
    • 事業説明
    • SWOT分析

第6章 エピジェネティック治療市場:付録

  • 市場定義
  • 略語集
  • 調査手法
  • 連絡先
  • 免責事項
  • 情報ソース

図表

目次
Product Code: GBIHC039MR

Abstract

Summary

GBI Research' s report, “Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma”, provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the technology that shape the industry dynamics for the key geographies: the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Further, the report provides competitive benchmarking for the leading companies and analyzes the licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research' s team of industry experts.

Scope

The scope of this report includes:

  • Annualized market data from 2001 to 2009, forecast forward to 2016.
  • Analysis of the leading technology in this space
  • Analysis of the leading technology in this space
  • Market characterization
  • Key drivers and barriers that have a significant impact on the market.
  • Competitive benchmarking of leading companies.

Reasons To Buy

The report will enhance your decision making capability.

It will allow you to:

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Companies Mentioned

  • Merck & Co.
  • Celgene Corporation
  • EISAI

Executive Summary

GBI Research, a leading business intelligence provider, has released its latest research, “Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma.” The report provides insights on segments where epigenetic therapies may prove to be useful. The report also details the market potential for the epigenetic therapies, Furthermore, it provides insights into the epigenetic therapeutics R&D pipeline. The report also contains comprehensive profiles of the epigenetic therapies in late-stage clinical development. The report offers insights into the US, the top five markets in Europe and Japan. The report also elucidates the current competitive landscape of the epigenetic therapeutics market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research' s team of industry experts.

Epigenetic drugs are the chemical compounds or biologics that cause epigenetic changes resulting in modified molecular protein expressions. These drugs have the potential to trigger or suppress a protein expression process.

Currently, there are four epigenetic drugs in the market, namely Vidaza, Zolinza, Dacogen and Istodax. The sales of these drugs will account for all of the revenues of the epigenetic therapeutics market. The global epigenetic therapeutics market measured in this report comprises the sales of VIdaza, Zolinza, and Dacogen in the top seven markets of the world.

Four Epigenetics Drugs Generated Revenues of $517m in 2009

Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009 - 2017

Source: GBI Research, Merck & Co, Celgene and Eisai annual reports

Vidaza, Dacogen, Zolinza and Istodax are the four currently approved epigenetic drugs in the market. The sales of these drugs amounted to $517m in 2009. Vidaza and Dacogen are approved for the indication Myelodysplastic Syndrome (MDS) and Zolinza and Istodax are approved for the indication Cutaneous T-cell lymphoma (CTCL). Of all the drugs, Vidaza had the largest market share in 2009, followed by Dacogen.

Vidaza and Dacogen Belong to a Class of Drugs called DNA Methyltransferase Inhibitors that Dominate the Epigenetics Market

Vidaza and Dacogen belong to a new class of drugs called DNA Methyltransferase inhibitors. These drugs cause the removal of the methyl group from the cytosine residue in the DNA and cause the repression of tumor genes. Of all the drugs, Vidaza and Dacogen are the most commonly used drugs for the treatment of MDS. They are currently employed by physicians as a second or third line of therapy.

The Epigenetic Therapies are Currently Only Approved for Blood Cancer

Epigenetic drugs are currently approved to treat MDS and CTCL, which are cancers of the blood cells. MDS is a type of blood cancer that affects the stem cells secreted in the bone marrow. CTCL affects the lymphocytes that secrete T-cells. The accumulation of the proliferated T-lymphocytes in the subcutaneous regions causes a rash-like appearance and progresses to become metastasis.

Vidaza' s Uptake is Projected to Grow. The Drug is Forecast to Reach $600m by 2017

Vidaza by Celgene is one of the therapies commonly employed to treat MDS. Vidaza' s uptake in the top seven markets will be driven by epidemiological factors and the escalation in Vidaza price. The annual cost of therapy ranges from $45,135 to $49,886. Thus, it is estimated to reach revenues of $604m by the year 2017.

Vidaza is in Phase III Clinical Trails for AML Treatment and it is Estimated to Have High Market Potential

Vidaza is in the late stage of clinical trials for the treatment of Acute Myeloid Leukemia (AML). AML is a rare disease that affects the blood cells. As Vidaza is approved for MDS, which is a precursor to AML, it is expected to be widely accepted after being approved for AML. Vidaza is estimated to achieve peak sales of $312m for AML by the year 2012 in the top seven markets.

Dacogen, Indicated for the Treatment of MDS, is Forecast to Reach $283m in Sales by 2017

Dacogen by Eisai is similar to Vidaza in terms of its mechanism of action and is indicated for the treatment of MDS. The annual cost of Dacogen treatment for MDS is $61,938, which is higher than Vidaza' s cost. Dacogen is employed as an alternative to Vidaza therapy in many cases, which leads to lower uptake. Thus, Dacogen is forecast to reach revenues of $283m by 2017, which is much lower than the estimates for Vidaza.

Zolinza, Indicated for the Treatment of CTCL, Will Reach $42m By 2017

Zolinza is indicated for the treatment CTCL which is a rare disease. The market for Zolinza as a CTCL therapy is expected to be steady throughout the forecast period. The annual cost of treatment ranges from $25,743 to $31,464 depending on the treatment period. The increase in the incidence and prevalence of the disease will drive the market from $21m in 2009 to $42m in 2017 at a Compound Annual Growth Rate (CAGR) of 10.7%.

Zolinza is Being Studied in More Than 61 Clinical Trails and is in Phase III for the Treatment of Multiple Myeloma

Zolinza is in Phase III clinical trials for the treatment of Multiple Myeloma (MM). The study is being conducted by Merck & Co. MM is a type of blood. The acceptance and uptake of Zolinza is expected to remain low as the growth in the acceptance and uptake of the drug is expected to be slow over the forecast period. Thus, the drug will achieve peak sales of $197m by 2017 for the MM market.

Istodax is Indicated for the Treatment of CTCL and is Estimated to Achieve Sales of $108m by 2017

Istodax by Celgene is indicated for the treatment of CTCL. The drug was approved in 2009. The average annual cost of therapy for the treatment of CTCL ranges from $36,777 to $44,950 depending on the treatment period. The drug is estimated to reach sales of $108m by 2017 at a CAGR of 16% for the period from 2010 to 2017. Certain epidemiological factors will support the growth of this market.

Table of Contents

1. Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. GBI Research Report Guidance

3. Market Characterization: Global Epigenetics Market

  • 3.1. Disease Overview
    • 3.1.1. Myelodysplastic Syndrome
    • 3.1.2. Cutaneous T-cell Lymphoma
  • 3.2. Epigenetic Drugs
  • 3.3. The US
  • 3.4. Top Five European Markets
  • 3.5. Japan

4. In-Depth Analysis

  • 4.1. Introduction
  • 4.2. Vidaza (Azacitidine)
    • 4.2.1. Indication
    • 4.2.2. Mechanism of Action
    • 4.2.3. Revenue Forecast
    • 4.2.4. Key Takeaway
    • 4.2.5. Market Potential
    • 4.2.6. Key Takeaway
    • 4.2.7. Pipeline Analysis
    • 4.2.8. Key takeaway
    • 4.2.9. Drug Profile
    • 4.3. Dacogen (Decitabine)
    • 4.3.1. Indication
    • 4.3.2. Mechanism of action
    • 4.3.3. Revenue Forecast
    • 4.3.4. Key Takeaway
    • 4.3.5. Market Potential
    • 4.3.6. Key Takeaway
    • 4.3.7. Pipeline Analysis
    • 4.3.8. Key Takeaway
    • 4.3.9. Drug Profile
    • 4.4. Zolinza (Vorinostat)
    • 4.4.1. Indication
    • 4.4.2. Mechanism of Action
    • 4.4.3. Revenue Forecast
    • 4.4.4. Key Takeaway
    • 4.4.5. Disease Overview
    • 4.4.6. Market Potential
    • 4.4.7. Key Takeaway
    • 4.4.8. Pipeline Analysis
    • 4.4.9. Key Takeaway
    • 4.4.10. Drug Profile
    • 4.5. Istodax (Romidepsin)
    • 4.5.1. Indication
    • 4.5.2. Disease Overview
    • 4.5.3. Mechanism of Action
    • 4.5.4. Market Potential
    • 4.5.5. Key Takeaway
    • 4.5.6. Pipeline Analysis
    • 4.5.7. Clinical Studies by Phases
    • 4.5.8. Clinical Studies by Indication
    • 4.5.9. Key Takeaway
    • 4.5.10. Drug Profile

5. Competitive Landscape

  • 5.1. Merck & Co.
    • 5.1.1. Company Overview
    • 5.1.2. Business Description
    • 5.1.3. SWOT
  • 5.2. Celgene Corporation
    • 5.2.1. Company Overview
    • 5.2.2. Business Description
    • 5.2.3. SWOT
  • 5.3. EISAI
    • 5.3.1. Company Overview
    • 5.3.2. Business Description
    • 5.3.3. SWOT

6. Epigenetic Therapeutics: Appendix

  • 6.1. Market Definitions
  • 6.2. Abbreviations
  • 6.3. Research Methodology
    • 6.3.1. Coverage
    • 6.3.2. Secondary Research
    • 6.3.3. Primary Research
    • 6.3.4. Forecasts
    • 6.3.5. Expert Panel Validation
  • 6.4. Contact Us
  • 6.5. Disclaimer
  • 6.6. Sources

List of Tables

  • Table 1: List of Approved Epigenetic Drugs, 2010
  • Table 2: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009 - 2017
  • Table 3: Epigenetic Therapeutics Market, by Geography, Revenue Forecast ($m) 2009 - 2017
  • Table 4: Epigenetic therapeutics Market, The US, Revenue Forecast ($m) 2009 - 2017
  • Table 5: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009- 2017
  • Table 6: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m), 2009 - 2017
  • Table 7: Vidaza - Snapshot, 2010
  • Table 8: Vidaza, Global, Revenue Forecast ($m) 2009 - 2017
  • Table 9: Vidaza, By Geography, Revenue Forecast ($m )2009 - 2017
  • Table 10: Vidaza, The US, Revenue Forecast ($m) 2009 - 2017
  • Table 11: Vidaza, Europe, Revenue Forecast ($m), 2009 - 2017
  • Table 12: Vidaza, Japan, Revenue Forecast ($m), 2009 - 2017
  • Table 13: Vidaza Market Potential, Global, Revenue Forecast ($m) 2012 - 2017
  • Table 14: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012 - 2017
  • Table 15: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012 - 2017
  • Table 16: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012 - 2017
  • Table 17: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012 - 2017
  • Table 18: Efficacy of Vidaza in MDS Patients, 2010
  • Table 19: Dacogen - Snapshot, 2010
  • Table 20: Dacogen, Global, Revenue Forecast ($m), 2009 - 2017
  • Table 21: Dacogen, By Geography, Revenue Forecast ($m), 2009 - 2017
  • Table 22: Dacogen, The US, Revenue Forecast ($m), 2009 - 2017
  • Table 23: Dacogen, Europe, Revenue Forecast ($m), 2009 - 2017
  • Table 24: Dacogen, Japan, Revenue Forecast ($m), 2009 - 2017
  • Table 25: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012 - 2017
  • Table 26: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012 - 2017
  • Table 27: Dacogen, Market Potential, The US, Revenue Forecast ($m), 2012 - 2017
  • Table 28: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012 - 2017
  • Table 29: Dacogen, Market Potential, Japan, Revenue Forecast ($m), 2012 - 2017
  • Table 30: Zolinza Snapshot, 2010
  • Table 31: Zolinza, Global, Revenue Forecast ($m), 2010 - 2017
  • Table 32: Zolinza, By Geography, Revenue Forecast ($m), 2010 - 2017
  • Table 33: Zolinza, The US, Revenue Forecast ($m), 2010 - 2017
  • Table 34: Zolinza, Europe, Revenue Forecast ($m), 2010 - 2017
  • Table 35: Zolinza, Japan, Revenue Forecast ($m), 2010 - 2017
  • Table 36: Zolinza Market Potential, By Geography, Revenue Forecast ($m), 2012 - 2017
  • Table 37: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012 - 2017
  • Table 38: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012 - 2017
  • Table 39: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012 - 2017
  • Table 40: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012 - 2017
  • Table 41: Istodax Snapshot, 2010
  • Table 42: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2010 - 2017
  • Table 43: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012 - 2017
  • Table 44: Istodax Market Potential, The US, Revenue Forecast ($m), 2010 - 2017
  • Table 45: Istodax Market Potential, Europe, Revenue Forecast ($m), 2010 - 2017
  • Table 46: Istodax Market Potential, The US, Revenue Forecast ($m), 2010 - 2017

List of Figures

  • Figure 1: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009 - 2017
  • Figure 2: Epigenetic therapeutics Market, by Geography, Revenue Forecast ($m) 2009 - 2017
  • Figure 3: Epigenetic Therapeutics Market, The US, Revenue Forecast ($m) 2009 - 2017
  • Figure 4: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009 - 2017
  • Figure 5: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m) 2009 - 2017
  • Figure 6: Vidaza, Global, Revenue Forecast ($m) 2009 - 2017
  • Figure 7: Vidaza, By Geography, Revenue Forecast ($m) 2009 - 2017
  • Figure 8: Vidaza, The US, Revenue Forecast ($m) 2009 - 2017
  • Figure 9: Vidaza, Europe, Revenue Forecast ($m) 2009 - 2017
  • Figure 10: Vidaza, Japan, Revenue Forecast ($m), 2009 - 2017
  • Figure 11: Vidaza Market Potential, Global, Revenue Forecast ($m), 2012 - 2017
  • Figure 12: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012 - 2017
  • Figure 13: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012 - 2017
  • Figure 14: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012 - 2017
  • Figure 15: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012 - 2017
  • Figure 16: Vidaza (Azacitidine) - Drug Pipeline, by Phase, 2010
  • Figure 17: Vidaza (Azacitidine) - Drug Pipeline, by Indication, 2009
  • Figure 18: Vidaza (Azacitidine) - Drug Pipeline, by Phase and Indication, 2010
  • Figure 19: Dacogen , Global, Revenue Forecast ($m), 2009 - 2017
  • Figure 20: Dacogen, By Geography, Revenue Forecast ($m), 2009 - 2017
  • Figure 21: Dacogen, The US, Revenue Forecast ($m), 2009 - 2017
  • Figure 22: Dacogen, Europe, Revenue Forecast ($m), 2009 - 2017
  • Figure 23: Dacogen, Japan, Revenue Forecast ($m), 2009 - 2017
  • Figure 24: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012 - 2017
  • Figure 25: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012 - 2017
  • Figure 26: Dacogen Market Potential, The US, Revenue Forecast ($m), 2012 - 2017
  • Figure 27: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012 - 2017
  • Figure 28: Dacogen Market Potential, Japan, Revenue Forecast ($m), 2012 - 2017
  • Figure 29: Dacogen (Decitabine) - Drug Pipeline, by Phase, 2010
  • Figure 30: Dacogen (Decitabine) - Drug Pipeline, by Indication, 2010
  • Figure 31: Dacogen (Decitabine) - Drug Pipeline, by Phase and Indication, 2010
  • Figure 32: Zolinza, Global, Revenue Forecast ($m), 2010 - 2017
  • Figure 33: Zolinza, Global, Revenue Forecast ($m), 2010 - 2017
  • Figure 34: Zolinza, The US, Revenue Forecast ($m), 2010 - 2017
  • Figure 35: Zolinza, Europe, Revenue Forecast ($m), 2010 - 2017
  • Figure 36: Zolinza, Japan, Revenue Forecast ($m), 2010 - 2017
  • Figure 37: Zolinza Market Potential, Global, Revenue Forecast ($m), 2012 - 2017
  • Figure 38: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012 - 2017
  • Figure 39: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012 - 2017
  • Figure 40: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012 - 2017
  • Figure 41: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012 - 2017
  • Figure 42: Zolinza (vorinostat) - Drug Pipeline, by Phase, 2010
  • Figure 43: Zolinza (vorinostat) - Drug Pipeline, by Indication, 2009
  • Figure 44: Zolinza (vorinostat) - Drug Pipeline, by Phase and Indication, 2010
  • Figure 45: Istodax Market Potential, Global, Revenue Forecast ($m), 2010 - 2017
  • Figure 46: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012 - 2017
  • Figure 47: Istodax Market Potential, The US, Revenue Forecast ($m), 2012 - 2017
  • Figure 48: Istodax Market Potential, Europe, Revenue Forecast ($m), 2012 - 2017
  • Figure 49: Istodax Market Potential, Japan, Revenue Forecast ($m), 2012 - 2017
  • Figure 50: Istodax (Romidepsin) - Drug Pipeline, by Phase, 2010
  • Figure 51: Istodax (Romidepsin) - Drug Pipeline, by Indication, 2010
  • Figure 52: Istodax (Romidepsin) - Drug Pipeline, by Phase and Indication, 2010
  • Figure 53: SWOT, Merck & Co, 2010
  • Figure 54: SWOT, Celgene Corporation, 2010
  • Figure 55: SWOT, Eisai, 2010
  • Figure 56: GBI Research Market Forecasting Model
Back to Top